115 related articles for article (PubMed ID: 38426558)
1. A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315.
Watts LP; Spencer SL
Cancer Discov; 2024 Mar; 14(3):386-388. PubMed ID: 38426558
[TBL] [Abstract][Full Text] [Related]
2. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
Dietrich C; Trub A; Ahn A; Taylor M; Ambani K; Chan KT; Lu KH; Mahendra CA; Blyth C; Coulson R; Ramm S; Watt AC; Matsa SK; Bisi J; Strum J; Roberts P; Goel S
Cancer Discov; 2024 Mar; 14(3):446-467. PubMed ID: 38047585
[TBL] [Abstract][Full Text] [Related]
3. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
4. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
[TBL] [Abstract][Full Text] [Related]
6. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
8. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
9. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
10. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
[TBL] [Abstract][Full Text] [Related]
12. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.
Marconett CN; Morgenstern TJ; San Roman AK; Sundar SN; Singhal AK; Firestone GL
Cancer Biol Ther; 2010 Aug; 10(4):397-405. PubMed ID: 20574166
[TBL] [Abstract][Full Text] [Related]
13. A confederacy of kinases: Cdk2 and Cdk4 conspire to control embryonic cell proliferation.
Hinds PW
Mol Cell; 2006 May; 22(4):432-3. PubMed ID: 16713571
[TBL] [Abstract][Full Text] [Related]
14. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
15. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.
Padmakumar VC; Aleem E; Berthet C; Hilton MB; Kaldis P
Mol Cell Biol; 2009 May; 29(10):2582-93. PubMed ID: 19307310
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
17. Mice thrive without Cdk4 and Cdk2.
Barrière C; Santamaría D; Cerqueira A; Galán J; Martín A; Ortega S; Malumbres M; Dubus P; Barbacid M
Mol Oncol; 2007 Jun; 1(1):72-83. PubMed ID: 19383288
[TBL] [Abstract][Full Text] [Related]
18. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.
Teixeira C; Pratt MA
Mol Endocrinol; 1997 Aug; 11(9):1191-202. PubMed ID: 9259311
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
